The US FDA has approved ensartinib for treating adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not been treated with an ALK inhibitor. Clinical evidence The safety and efficacy of ensartinib were evaluated in a clinical trial involving 290 NSCLC patients. Ensartinib significantly improved progression-free survival (PFS) compared to crizotinib (HR – 0.56), with median PFS durations of 25.8 months vs.
12.7 months. However, no significant difference was found in overall survival between the ensartinib and crizotinib groups. Dosage and administration Available as capsules 225 mg orally once daily with or without food Contraindications – Hypersensitivity reaction to ensartinib Warnings and precautions Interstitial lung disease/Pneumonitis Hepatotoxicity Dermatologic adverse reaction Bradycardia Hyperglycemia…
